CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 667 enrolled
Drug / intervention
Atezolizumabdrug
Likely dose
Atezolizumab 1200 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02031458
NCT02031458Phase 2Completed
CompareCT.gov

A Phase II, Multicenter, Single-Arm Study OF Atezolizumab In Patients With PD-L1-Positive Locally Advanced Or Metastatic Non-Small Cell Lung Cancer

Hoffmann-La Roche·interventional·Posted Jan 9, 2014·Updated Jan 6, 2020

In Brief

A Phase 2 clinical trial evaluating Atezolizumab for Non-Small Cell Lung Cancer. Completed, enrolled 667 participants across 110 sites in 19 countries.

Detailed Summary

This multicenter, single-arm study will evaluate the efficacy and safety of Atezolizumab in participants with PD-L1-positive locally advanced or metastatic non-small cell lung cancer (NSCLC). Participants will receive Atezolizumab 1200 milligrams (mg) intravenously every 3 weeks as long as participants are experiencing clinical benefit as assessed by the investigator, that is , in the absence of unacceptable toxicity or symptomatic deterioration attributed to disease progression.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNon-Small Cell Lung Cancer
CountriesAustralia, Belgium, Bosnia and Herzegovina, Bulgaria, Canada, France, Georgia, Germany, Hong Kong, Italy, Japan, Netherlands, Singapore, Slovenia, Spain, Switzerland, Turkey (Türkiye), United Kingdom, United States
Collaborators--

Timeline

Phase 2CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedJan 9, 2014
Enrollment StartJan 22, 2014
Primary CompletionMay 28, 2015
Study CompletionJan 11, 2019
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 12.5 years ago

Interventions

Atezolizumabdrug

1200 mg IV every 3 weeks